The article presents alternative approaches to COVID-19 vaccine procurement in the U.S. Topics discussed include concern regarding risk of failure or delay in proving safety and efficacy; acceleration of manufacturing which involves substantial, risky investment, and carefully crafted public intervention; and optimal portfolio of vaccine investments.
Publication:
American Economic Association Papers and Proceedings